AyoxxA Biosystems, an international biotech company based in Cologne, Germany, and Singapore has developed a proprietary technology platform for multiplexed protein analysis. Core to the cutting-edge system is a bead-based technology that yields 10,000-fold more data points than a standard 384-well ELISA plate. Together with a lower sample volume, better accuracy and a higher dynamic range this will be the new gold standard in proteomics. Full automation for high throughput and readout with existing equipment lead to attractive cost and time savings – for biomedical research, pharmacological screening and preclinical diagnostics development. In addition to multiple grants from MIT and Singapore, AyoxxA raised a series A investment of 3 M EUR with Wellington Partners as the lead investor.